Drug Type CAR-T |
Synonyms BMS-986515 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Inflammatory Myopathies | Phase 1 | United States | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Australia | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Brazil | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Czechia | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | France | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Germany | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Israel | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Poland | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Romania | 23 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | Spain | 23 Aug 2025 |